B-cell lymphoma belongs to non-Hodgkin’s lymphoma, a type of malignant tumor with a five-year survival rate of about 60% to 70% according to the 2022 guidelines for the treatment of B-cell lymphoma, but there is individual variability.
B-cell lymphoma is a type of lymphoma, a malignant tumor of the hematopoietic system, which may manifest as painless progressive lymph node enlargement with or without low-grade fever, night sweats, and malaise, and the diagnosis is usually confirmed by pathological biopsy of the lymph nodes.
If the tumor can be actively treated at the early stage of the disease by applying chemotherapy, targeted therapy and other programs, it may be able to reach the standard of cure. If the tumor is more limited, surgery can also be actively used, and the cure rate is also relatively high.
However, for patients with advanced B-cell lymphoma, the treatment plan mainly focuses on maintenance therapy, and radiotherapy and immunotherapy may not be able to achieve more obvious therapeutic effect, and can only be considered to prolong the life of patients and improve the quality of their survival.
Whether B-cell lymphoma can be cured or not needs to be decided according to the actual situation of the patient, if diagnosed with B-cell lymphoma, it is recommended to seek medical treatment as soon as possible and carry out the treatment under the guidance of professional doctors, so as to avoid delaying the condition.